<DOC>
	<DOCNO>NCT00675688</DOCNO>
	<brief_summary>The purpose study determine whether bazedoxifene/conjugated estrogen combination effective prevention endometrial hyperplasia prevention osteoporosis postmenopausal woman .</brief_summary>
	<brief_title>Study Evaluating Safety Efficacy Bazedoxifene/Conjugated Estrogens Combinations Postmenopausal Women</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Hyperplasia</mesh_term>
	<mesh_term>Raloxifene Hydrochloride</mesh_term>
	<mesh_term>Bazedoxifene</mesh_term>
	<mesh_term>Estrogens , Conjugated ( USP )</mesh_term>
	<mesh_term>Estrogens</mesh_term>
	<criteria>Generally healthy , postmenopausal woman age 40 75 year inclusive Intact uterus Last natural menstrual cycle ( without exogenous hormone therapy ) complete least 12 consecutive month screen A history active presence thrombophlebitis , thrombosis thromboembolic disorder A history active presence cerebrovascular accident , stroke , transient ischemic attack A history active presence malignancy , treatment malignancy , within previous 10 year Additional criterion applies .</criteria>
	<gender>Female</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Menopause</keyword>
</DOC>